A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+ tumor cells

mAbs

Volumn 7, Issue 3, 2015, Pages 584-604

  Reusch, Uwe ^a   Duell, Johannes ^b   Ellwanger, Kristina ^a   Herbrecht, Carmen ^a   Knackmuss, Stefan H J ^a   Fucek, Ivica ^a   Eser, Markus ^a,d   McAleese, Fionnuala ^a,d   Molkenthin, Vera ^c   Le Gall, Fabrice ^a,e   Topp, Max ^b   Little, Melvyn ^a   Zhukovsky, Eugene A ^a  

^a Affimed GmbH   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Abcheck Sro   (Czech Republic)

^d BAYER PHARMA AG   (Germany)

^e Ganymed Pharmaceuticals AG   (Germany)

Author keywords

ALL; Bispecific antibodies; CD3; Non Hodgkin lymphoma; T cells

Indexed keywords

AFM11; ALBUMIN; CANCER ANTIBODY; CD19 ANTIGEN; CD69 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 6; MONOCLONAL ANTIBODY CD3; PHYTOHEMAGGLUTININ; RECOMBINANT ANTIBODY; TETRAVALENT BISPECIFIC TANDEM DIABODY; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CD3 ANTIGEN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASSOCIATION RATE CONSTANT; CHEMILUMINESCENCE IMMUNOASSAY; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; CYTOTOXICITY ASSAY; EC50; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; SIZE EXCLUSION CHROMATOGRAPHY; T LYMPHOCYTE ACTIVATION; TISSUE DISTRIBUTION; TUMOR CELL DESTRUCTION; TUMOR XENOGRAFT; WHOLE BODY AUTORADIOGRAPHY; ANIMAL; CHEMISTRY; CHO CELL LINE; CRICETULUS; DRUG SCREENING; HAMSTER; HEK293 CELL LINE; IMMUNOLOGY; JURKAT CELL LINE; MALE; NEOPLASMS, EXPERIMENTAL; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, NEOPLASM; ANTIGENS, CD19; ANTIGENS, CD3; CHO CELLS; CRICETINAE; CRICETULUS; HEK293 CELLS; HUMANS; JURKAT CELLS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASMS, EXPERIMENTAL; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938506999     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2015.1029216     Document Type: Article

References (42)

1. Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, Leonard JE, McClure A, Weaver R, Cairelli S, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000; 1: 1-9; PMID: 11467356; http://dx. doi. org/10. 2174/1389201003379059.
2. Alduaij W, Illidge TM. The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood 2011; 117: 2993-3001; PMID: 21209380; http://dx. doi. org/10. 1182/blood-2010-07-298356.
3. Illidge T, Cheadle EJ, Donaghy C, Honeychurch J. Update on obinutuzumab in the treatment of B-cell malignancies. Expert Opin Biol Ther 2014; 14: 1507-17; PMID: 25190612; http://dx. doi. org/10. 1517/14712598. 2014. 948414.
4. Remer M, Al-Shamkhani A, Glennie M, Johnson P. Mogamulizumab and the treatment of ccr4-positive tcell lymphomas. Immunotherapy 2014; 6: 1187-206; PMID: 25496334; http://dx. doi. org/10. 2217/imt. 14. 94.
5. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68: 8049-57; PMID: 18829563; http://dx. doi. org/10. 1158/0008-5472. CAN-08-2268.
6. Maus MV, Grupp SA, Porter DL, June CH. Antibodymodified T cells: cars take the front seat for hematologic malignancies. Blood 2014; 123: 2625-35; PMID: 24578504; http://dx. doi. org/10. 1182/blood-2013-11-492231.
7. Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010; 2: 129-36; PMID: 20190561; http://dx. doi. org/10. 4161/mabs. 2. 2. 11221.
8. Buhmann R, Michael S, Juergen H, Horst L, Peschel C, Kolb H. Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigatordriven. J Transl Med 2013; 11: 160; PMID: 23815981; http://dx. doi. org/10. 1186/1479-5876-11-160.
9. Topp MS, N Goekbuget N, Stein AS, Bargou RC, Dombret H, Fielding AK, Ribera JM, Foá F, Zugmaier G, Holland C, et al., Confirmatory openlabel, singlearm, multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts) with relapsed/refractory Bprecursor acute lymphoblastic leukemia (r/r ALL). J Clin Oncol 2014; 32: 5s (suppl; abstr 7005); PMID: 24190110; http://dx. doi. org/10. 1200/JCO. 2014. 56. 3247.
10. Nagorsen D, Baeuerle PA. Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab. Exp Cell Res 2011; 317: 1255-60; PMID: 21419116; http://dx. doi. org/10. 1016/j. yexcr. 2011. 03. 010.
11. Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS, Gökbuget N, Neumann S, Goebeler M, Viardot A, et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119: 6226-33; PMID: 22592608; http://dx. doi. org/10. 1182/blood-2012-01-400515.
12. Portell CA, Wenzell CM, Advani AS. Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia. Clin Pharmacol 2013; 5: 5-11; PMID: 23671399; http://dx. doi. org/10. 2147/CPAA. S42689.
13. Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010; 59: 1197-209; PMID: 20309546; http://dx. doi. org/10. 1007/s00262-010-0844-y.
14. Beverley PC, Callard RE. Distinctive functional characteristics of human "T" lymphocytes defined by e rosetting or a monoclonal anti-T cell antibody. Eur J Immunol 1981; 11: 329-34; PMID: 6788570; http://dx. doi. org/10. 1002/eji. 1830110412.
15. Pezzutto A, Dörken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced b cell activation and proliferation. J Immunol 1987; 138: 2793-9; PMID: 2437199.
16. Schwarz M, Röttgen P, Takada Y, Le Gall F, Knackmuss S, Bassler N, Büttner C, Little M, Bode C, Peter K. Single-chain antibodies for the conformation-specific blockade of activated platelet integrin alphaiibbeta3 designed by subtractive selection from naive human phage libraries. FASEB J 2004; 18: 1704-6; PMID: 15522915.
17. Honegger A, Plückthun A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J Mol Biol 2001; 309: 657-70; PMID: 11397087; http://dx. doi. org/10. 1006/jmbi. 2001. 4662.
18. Padlan EA, Abergel C, Tipper JP. Identification of specificity-determining residues in antibodies. FASEB J 1995; 9: 133-9; PMID: 7821752.
19. Kufer P, Lutterbüse R, Kohleisen B, Zeman S, Bäuerle P, inventors; Micromet AG, assignee. Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders. World patent WO2004/106381. 2004 Dec 9. English.
20. Traunecker A, Lanzavecchia A, Karjalainen K. Bispecific single chain molecules (janusins) target cytotoxic lymphocytes on HIV infected cells. EMBO J 1991; 10: 3655-9; PMID: 1834458.
21. Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, et al. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011; 117: 4542-51; PMID: 21300981; http://dx. doi. org/10. 1182/blood-2010-09-306449.
22. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100: 690-7; PMID: 12209608; http://dx. doi. org/10. 1002/ijc. 10557.
23. Nagorsen D, Kufer P, Baeuerle PA, Bargou R. Blinatumomab: a historical perspective. Pharmacol Ther 2012; 136: 334-42; PMID: 22940266; http://dx. doi. org/10. 1016/j. pharmthera. 2012. 07. 013.
24. Document: Blinatumomab (AMG 103) Background information for the pediatric subcommittee of the oncologic drugs advisory committee meeting 04 December 2012 [Internet]. Silver Spring (MD): U. S. Food and Drug Administration (US); 2012. Available from: http://www. fda. gov/downloads/AdvisoryCom mittees/CommitteesMeetingMaterials/Drugs/Oncolo gicDrugsAdvisoryCommittee/UCM330210. pdf.
25. Hoffmann P, Hofmeister R, Brischwein K, Brandl C, Crommer S, Bargou R, Itin C, Prang N, Baeuerle PA. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115: 98-104; PMID: 15688411; http://dx. doi. org/10. 1002/ijc. 20908.
26. Tax WJ, Hermes FF, Willems RW, Capel PJ, Koene RA. Fc receptors for mouse igg1 on human monocytes: polymorphism and role in antibody-induced t cell proliferation. J Immunol 1984; 133: 1185-9; PMID: 6235283.
27. Ceuppens JL, Bloemmen FJ, Van Wauwe JP. T cell unresponsiveness to the mitogenic activity of okt3 antibody results from a deficiency of monocyte fc gamma receptors for murine igg2a and inability to cross-link the t3-ti complex. J Immunol 1985; 135: 3882-6; PMID: 2933454.
28. Smith KG, Austyn JM, Hariri G, Beverley PC, Morris PJ. T cell activation by anti-t3 antibodies: comparison of igg1 and igg2b switch variants and direct evidence for accessory function of macrophage fc receptors. Eur J Immunol 1986; 16: 478-86; PMID: 2938973; http://dx. doi. org/10. 1002/eji. 1830160503.
29. Verwilghen J, Baroja ML, Van Vaeck F, Van Damme J, Ceuppens JL. Differences in the stimulating capacity of immobilized anti-cd3 monoclonal antibodies: variable dependence on interleukin-1 as a helper signal for t-cell activation. Immunology 1991; 72: 269-76; PMID: 1826671.
30. Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SHJ, Kiprijanov S, Little M, Zhukovsky EA. A novel tetravalent bispecific tandab (CD30/CD16a) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 2014; 6: 728-39; PMID: 24670809.
31. Rothe A, Topp MS, Eichenauer DA, von Tresckow B, Hummel H, Ravic M, Marschner J, Engert A. Updated phase I data of afm13: a bispecific tandem antibody (tandab) in relapsed/refractory (r/r) hodgkin lymphoma (hl). J Clin Oncol 2014; 32: (suppl; abstr 3025).
32. Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, Horst H, Raff T, Viardot A, Schmid M, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-8; PMID: 21576633; http://dx. doi. org/10. 1200/JCO. 2010. 32. 7270.
33. Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, Kufer P, Lutterbüse R, Riethmüller G, Gjorstrup P, et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific singlechain antibody construct. J Immunol 2003; 170: 4397-402; PMID: 12682277; http://dx. doi. org/10. 4049/jimmunol. 170. 8. 4397.
34. Engelhardt B, Ransohoff RM. Capture, crawl, cross: the T cell code to breach the blood-brain barriers. Trends Immunol 2012; 33: 579-89; PMID: 22926201; http://dx. doi. org/10. 1016/j. it. 2012. 07. 004.
35. Feng S, Huang Y, Chen Z. Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia?. Med Hypotheses 2011; 76: 618-21; PMID: 21398042; http://dx. doi. org/10. 1016/j. mehy. 2010. 12. 001.
36. Ye J, Ma N, Madden TL, Ostell JM. IgBLAST: an immunoglobulin variable domain sequence analysis tool. Nucleic Acids Res 2013; 41: W34-40; PMID: 23671333; http://dx. doi. org/10. 1093/nar/gkt382.
37. Mack M, Riethmüller G, Kufer P. A small bispecific antibody construct expressed as a functional singlechain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A 1995; 92: 7021-5; PMID: 7624362; http://dx. doi. org/10. 1073/pnas. 92. 15. 7021.
38. Kjer-Nielsen L, Dunstone MA, Kostenko L, Ely LK, Beddoe T, Mifsud NA, Purcell AW, Brooks AG, McCluskey J, Rossjohn J. Crystal structure of the human t cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mab OKT3. Proc Natl Acad Sci U S A 2004; 101: 7675-80; PMID: 15136729; http://dx. doi. org/10. 1073/pnas. 0402295101.
39. Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD, Bairoch A. Protein identification and analysis tools on the ExPASy server. In John M. Walker, ed., The Proteomics Protocols Handbook. Totowa, NJ: Humana Press; 2005; 571-607.
40. Kontula K, Paavonen T, Vuopio P, Andersson LC. Glucocorticoid receptors in hairy-cell leukemia. Int J Cancer 1982; 30: 423-6; PMID: 7141737; http://dx. doi. org/10. 1002/ijc. 2910300407.
41. Carlsson G, Gullberg B, Hafström L. Estimation of liver tumor volume using different formulas-an experimental study in rats. J Cancer Res Clin Oncol 1983; 105: 20-3; PMID: 6833336; http://dx. doi. org/10. 1007/BF00391826.
42. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-5; PMID: 8378254; http://dx. doi. org/10. 1023/A: 1018943613122.